Source: BioSpace , PharmaTimes, Ophthalmology
Area: News
The full two year data from the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) which compared bevacizumab (AvastinT) and ranibizumab (LucentisT) intravitreal injections for neovascular age-related macular degeneration (AMD) have been reported. [The study design and one year data have been reported previously - see NELM abstract below.]
The following findings were noted:
. The proportion of patients with one or more systemic serious adverse events was significantly higher with bevacizumab than ranibizumab (234 [39.9%] vs. 190 [31.7%]; adjusted risk ratio, 1.30; 95% CI, 1.07?1.57; P = 0.004).
. Gastrointestinal disorders (e.g., haemorrhage, hernia, nausea, and vomiting), were significantly higher in bevacizumab treated patients (11 (1.8%) ranibizumab-treated vs 28 (4.8%) bevacizumab-treated patients; P = 0.005).
. Venous thrombotic events occurred in 3 (0.5%) ranibizumab-treated patients and in ...
Uncategorized